Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients.
暂无分享,去创建一个
Zhensheng Liu | H. Heslop | C. Rooney | A. Gee | M. Brenner | J. Goss | B. Savoldo | M. H. Huls | Z. Liu | S. Doster | Sheri Doster
[1] R. Busuttil,et al. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. , 2000, Transplantation.
[2] T. Kataoka,et al. Involvement of FK506-sensitive and insensitive granule exocytosis pathways in perforin-dependent target cell lysis mediated by a CD8+ CTL clone. , 2000, Immunology letters.
[3] Zhensheng Liu,et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. , 2000, Blood.
[4] F. Baldanti,et al. High Levels of Epstein-Barr Virus DNA in Blood of Solid-Organ Transplant Recipients and Their Value in Predicting Posttransplant Lymphoproliferative Disorders , 2000, Journal of Clinical Microbiology.
[5] V. Leblond,et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] I. Flinn,et al. Application of the ELISPOT assay to the characterization of CD8(+) responses to Epstein-Barr virus antigens. , 2000, Blood.
[7] R. Gascoyne,et al. Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation , 1999, The Lancet.
[8] K. Fujii,et al. Rapid Determination of Epstein-Barr Virus–Specific CD8+T-Cell Frequencies by Flow Cytometry , 1999 .
[9] D. Crawford,et al. THE ROLE OF ADOPTIVE IMMUNOTHERAPY IN THE PREVENTION AND TREATMENT OF LYMPHOPROLIFERATIVE DISEASE FOLLOWING TRANSPLANTATION , 1999, British journal of haematology.
[10] D. Czerwinski,et al. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[11] G. Mazariegos,et al. Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease. , 1998, Transplantation.
[12] D. Srivastava,et al. Infusion of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virus–Induced Lymphoma in Allogeneic Transplant Recipients , 1998 .
[13] D. Thorley-Lawson,et al. EBV persistence in memory B cells in vivo. , 1998, Immunity.
[14] A. Burroughs,et al. Reconstitution of EBV-specific T cell immunity in solid organ transplant recipients. , 1998, Journal of immunology.
[15] S Kimbrough,et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. , 1998, Blood.
[16] H. Antunes,et al. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. , 1997, Transplantation.
[17] D. Moss,et al. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. , 1997, Annual review of immunology.
[18] H. Heslop,et al. Adoptive immunotherapy for Epstein-Barr virus-related lymphoma. , 1996, Leukemia & lymphoma.
[19] P. Doherty,et al. Progressive loss of CD8+ T cell-mediated control of a gamma-herpesvirus in the absence of CD4+ T cells , 1996, The Journal of experimental medicine.
[20] Malcolm K. Brenner,et al. Long–term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene–modified virus–specific T lymphocytes , 1996, Nature Medicine.
[21] N. Harris,et al. Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin. , 1995, American journal of clinical pathology.
[22] R. Krance,et al. Early identification of Epstein‐Barr virus‐associated post‐transplantation lymphoproliferative disease , 1995, British journal of haematology.
[23] R. Ahmed,et al. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection , 1994, Journal of virology.
[24] S. Riddler,et al. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. , 1994, Blood.
[25] K. Pfeffer,et al. V delta 1+ subset of human gamma delta T cells responds to ligands expressed by EBV-infected Burkitt lymphoma cells and transformed B lymphocytes. , 1992, Journal of immunology.
[26] E. Kieff,et al. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies , 1992, The Journal of experimental medicine.
[27] N. Sigal,et al. Cyclosporin A, FK-506, and Rapamycin: Pharmacologic Probes of Lymphocyte Signal Transduction , 1992 .
[28] D. Crawford,et al. Effect of FK 506 on Epstein-Barr virus specific cytotoxic T cells , 1991, The Lancet.
[29] M. Allday,et al. Epstein-Barr virus-associated lymphoproliferative disorders in immunocompromised individuals. , 1991, Advances in cancer research.
[30] R. Fisher,et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. , 1990, The New England journal of medicine.
[31] P. Paoli,et al. γδ T Cell Receptor-Bearing Lymphocytes during Epstein-Barr Virus Infection , 1990 .
[32] J. Bluestone,et al. TCR gamma delta cells--minor redundant T cell subset or specialized immune system component? , 1989, Journal of immunology.
[33] L. Young,et al. Two families of sequences in the small RNA-encoding region of Epstein-Barr virus (EBV) correlate with EBV types A and B , 1989, Journal of virology.
[34] T. Starzl,et al. THE FREQUENCY OF EPSTEIN‐BARR VIRUS INFECTION AND ASSOCIATED LYMPHOPROLIFERATIVE SYNDROME AFTER TRANSPLANTATION AND ITS MANIFESTATIONS IN CHILDREN , 1988, Transplantation.
[35] A. Wood,et al. Pharmacologic aspects of cyclosporine therapy: pharmacokinetics. , 1985, Transplantation proceedings.
[36] R. Simmons,et al. Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation. , 1985, Transplantation.
[37] The effects of cyclosporin A on the immune system. , 1985, Annual review of immunology.
[38] R. Blaese,et al. Selective inhibition of immunoregulatory cell functions by cyclosporin A. , 1982, Journal of immunology.